Positron executes MOU with Noblesville, Indiana. Qiagen Reaches Agreement To Buy Stake In Ipsogen. Print E-mail
By Staff and Wire Reports   
Friday, 08 July 2011 19:55
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 8, 2011.

Positron Corporation (OTC:POSC) has executed a Memorandum of Understanding (“MOU”) with the City of Noblesville, Indiana to relocate its corporate headquarters, research & development and product manufacturing facilities to Noblesville. Included in the MOU are economic incentives for the development of the Company’s high energy 70 MeV cyclotron project and radiopharmaceutical manufacturing facility also to be located in Noblesville.

Positron is proposing to make a capital investment of approximately $55 million dollars for this project in conjunction with significant economic development incentives from the City of Noblesville and the State of Indiana, as well as various other project financing opportunities.

This cyclotron, once completed, will be the highest energy commercial cyclotron for isotope production within the United States and will advance Positron’s objectives for the production of medical isotopes and radiopharmaceuticals used in cardiac PET imaging, diagnostic and therapeutic medical radiopharmaceuticals. This project is the most significant endeavor in the Company’s history and strengthens Positron’s position in the marketplace; which will have far-reaching implications in the nuclear cardiology industry.

----

Qiagen NV (NASDAQ:QGEN) announced it has entered into binding agreements with a group of major shareholders of Ipsogen S.A. to purchase approximately 61% of the molecular profiling and personalized healthcare diagnostics for a broad range of applications in the field of hematology.

The agreements announced between QIAGEN and the group of major shareholders of Ipsogen S.A. are made under the terms of this initial announcement. QIAGEN expects to complete these transactions to acquire this Ipsogen stake of approximately 61% on or about July 12, 2011. Upon completion of this step, Ipsogen would become a fully consolidated subsidiary of QIAGEN.

The agreement follows a public announcement on June 15, 2011, when QIAGEN announced it was in exclusive negotiations to purchase an initial stake in Ipsogen from these shareholders for EUR12.90 per share. QIAGEN announced at that time it would subsequently initiate a public tender offer for the remaining shares at the same price if the offer was accepted.


Also Friday:


Allezoe Medical Holdings, Inc. (OTCBB:ALZM) today announces that at a meeting of the Board of Directors held on July 6, 2011, Michael Holder resigned as Chief Executive Officer of Allezoe so that he could devote his full attention to the development of the Organ Transport Systems' LifeCradle® technology.

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2011 earnings conference call on Tuesday, August 2, 2011, 8:00 – 9:00 a.m. (ET).

BioTech Medics, Inc., (PINKSHEETS: BMCS) announced today that it has been notified by a FINRA Dispute Resolution Arbitration Judge that BioTech has been Awarded $1,788,841.00 in compensatory damages, plus 6% per annum pre-award interest from November 8, 2007, plus post interest, legal and filing fees.

Deaf-Talk, Inc., dba DT Interpreting (PINKSHEETS: MGQG) (DTI), the industry leader in on-demand video sign language interpreting, today announced the release of its financial statements, which are unaudited at this time.

Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Wednesday, August 3, 2011 at 4:30 p.m. ET to review the second quarter 2011 financial results.

Medistem Inc. (PINKSHEETS: MEDS) reported today publication of a peer-reviewed manuscript in collaboration with the Tissue Engineering, Regenerative Medicine and Cell Therapies Laboratory, CUCAIBA, of the Argentinean Ministry of Health describing a previously unreported link between metabolic syndrome, lipodystrophy, and aging.

Northwest Biotherapeutics (OTC Bulletin Board:NWBO) ("NWBT") announced today a $4.55 million equity investment on June 28, 2011, by The Richard M. Schulze Family Foundation (the "Foundation").

QIAGEN N.V. (NASDAQ:QGEN) today announced it has entered into binding agreements with a group of major shareholders of Ipsogen S.A. (Alternext: ALIPS) to purchase approximately 61% of the global leader in molecular profiling and personalized healthcare diagnostics for a broad range of applications in the field of hematology.

RegenoCELL Therapeutics, Inc. (OTCBB: RCLL), a leader in adult stem cell therapy, is pleased to announce the opening of another state of the art facility in Greece for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter